Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate

MT Newswires Live
03-04

Tiziana Life Sciences (TLSA) said Tuesday it filed an investigational new drug application for foralumab, a potential treatment for amyotrophic lateral sclerosis, with the US Food and Drug Administration.

The application is supported by a grant from the ALS Association as part of the Hoffman ALS Clinical Trial Awards Program, the company said.

The company's development programs for Foralumab, a nasal anti-CD3 monoclonal antibody, are also being focused on multiple sclerosis and Alzheimer's disease.

Upon getting the agency's clearance, Tiziana said it plans to begin a 20-patient clinical trial of two doses of intranasal foralumab aimed at evaluating the safety and early-stage parameters of disease improvement in amyotrophic lateral sclerosis.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10